E merging evidence indicates that activation of innate immunity signaling is critical for myocardial adaptation to stress. 1 One such highly evolutionary conserved pathway is activated by tumor necrosis factor (TNF), the prototypical member of the TNF superfamily of ligands. 2 Indeed, TNF pretreatment, or activation of either TNFR1 or TNFR2 receptor, prevents hypoxia/reperfusion-induced cell death in mammalian cardiomyocytes, in-vitro 3 ; and transgenic expression or exogenous administration of low doses of TNF attenuates ex vivo cardiac ischemia/reperfusion (I/R) injury. 4, 5 Also, absence of both TNFR1 and TNFR2 receptors increases I/R-induced cardiomyocyte death, ex vivo, 4 and results in marked increase in infarct size with in vivo coronary ligation as compared with controls, 6 pointing to a redundancy in cytoprotective signaling triggered by TNF via its cognate receptors. In this context, it is notable that TNF receptor-associated factor 2 (TRAF2), a scaffolding protein, is recruited to both TNF receptors on their activation, 7 and its transgenic expression (at low levels) attenuates cardiomyocyte death with experimental ex vivo I/R injury. 4 Although these data suggest that TRAF2 may facilitate cytoprotective signaling downstream of both TNF receptors, the underlying mechanisms remain largely unknown, despite extensive investigation. [3] [4] [5] evolutionarily conserved prosurvival pathway that sequesters damaged mitochondria within autophagosomes resulting in their intralysosomal degradation (by mitophagy), which is essential to protect against cardiomyocyte death in myocardial infarction. 9, 10 Activation of mitophagy also plays a central role in ischemia preconditioning. 11 TNF signaling is implicated in induction of cardiomyocyte autophagy, which is cytoprotective against lipopolysaccharide-induced cell death. 12 Whether TNF induces mitophagy or signals via TRAF2 to promote mitochondrial autophagy is not known.
Ubiquitination of mitochondrial proteins in response to mitochondrial damage is essential for their sequestration and degradation within the lysosomes. 13 PARKIN, an E3 ubiquitin ligase, is recruited to damaged mitochondria via activation by PINK1 (PTEN-induced putative kinase 1, a serine-threonine kinase), and ubiquitinates mitochondrial proteins. 14, 15 However, although targeted ablation of PINK1 in cardiac myocytes results in mitochondrial abnormalities and cardiomyopathy, 16 loss of PARKIN is well tolerated in the unstressed state, 17 suggesting that other E3 ubiquitin ligases may be involved in removal of damaged mitochondria. Relevant to this discussion is the observation that TRAF2, an E3 ubiquitin ligase, 18 is recruited to the mitochondria by mitochondrial antiviral signalosome, a mitochondrially localized protein with multiple scaffolding domains, [19] [20] [21] after activation of innate immune signaling pathways. Therefore, we tested the hypothesis that TRAF2 mediates mitochondrial autophagy. Here, we show for the first time that TRAF2 is present on the mitochondria in resting cardiac myocytes, and functions in concert with PARKIN as an E3 ubiquitin ligase to facilitate autophagic removal of damaged mitochondria, raising the intriguing possibility that TRAF2-mediated mitophagy may be an important determinant of cytoprotective TNF signaling in I/R injury.
Methods
Neonatal rat cardiac myocyte (NRCM) cultures were prepared as described. 22, 23 MHCsTNF mice with cardiomyocyte-specific overexpression of wild-type (secretable) TNF were described previously. 24 In vivo I/R injury was performed in adult male C57Bl6 mice, as described. 22 All animal studies were approved by the Animal Studies Committee at Washington University School of Medicine and by the Institutional Animal Care and Use Committee at the John Cochran VA Medical Center. Hypoxia/reoxygenation modeling, generation of adenoviral constructs, immunofluorescence, and electron microscopy imaging, quantitative polymerase chain reaction analysis, flow cytometry, subcellular fractionation, assessment of mitochondrial DNA content, citrate synthase assays, immunoblotting, and assessment of cell death were performed as previously described, 22 with details described in Methods in the Data Supplement.
Statistical Analysis
Post hoc pairwise comparison results are expressed as mean±SEM. Statistical differences were assessed with the unpaired 2-tailed Student t test for 2 experimental groups, 1-way ANOVA for multiple groups; and 2-way ANOVA for testing 2 variables across multiple groups, with the SPSS software. Bonferroni post hoc pairwise comparison adjustment was used after ANOVA for testing for significant differences between groups. Assumptions of normality were verified with visual examination of the residuals via histograms and the Shapiro-Wilk test; and variance was assessed by using the Levene test for equality of variances for t test and the Levene homogeneity of variance test for ANOVA, using SPSS software. Nonparametric tests (Mann-Whitney and Kruskal-Wallis) were used for data that was not normally distributed (in lieu of t test and 1-way ANOVA, respectively); and Dunnett T3 post hoc analysis was applied after 1-way ANOVA for data demonstrating unequal variance. A 2-tailed P value of <0.05 was considered statistically significant.
Results

TNF Induces Mitochondrial Autophagy With Increased TRAF2 Localization to Mitochondria
Previous studies indicate that TNF treatment is sufficient to induce autophagy in cardiomyocytes. 12 We confirmed that TNF treatment induces autophagy in isolated NRCMs with progressive increase in levels of autophagosome-bound LC3-II ( Figure 1A ) and decline in p62 (an adaptor protein that gets consumed during autophagy; Figure 1A ; Figure Figure 1C ), paralleling the induction of autophagy. Guided by recent data demonstrating that TRAF2 is targeted to the mitochondria either as a part of the death-inducing signaling complex on TNF stimulation 25, 26 or via its interactions with a scaffolding protein, mitochondrial antiviral signaling, after activation of innate immune responses, [19] [20] [21] we examined whether TRAF2 localizes to mitochondria in cardiac myocytes. We found that endogenous TRAF2 cosegregates with cytochrome oxidase IV (COX IV), which is an inner mitochondrial membranelocalized respiratory chain protein ( Figure 1D ) in unstimulated NRCMs, and colocalizes with translocase of outer mitochondrial membrane 20 homologue ( Figure 1E ; Figure  IIA in the Data Supplement), an outer mitochondrial membrane protein, as well as with COX IV (Figure IIB and IIC in the Data Supplement) on confocal microscopy, indicating that it is present on the mitochondria in the resting state. Notably, TNF treatment increased the relative abundance of TRAF2 in the mitochondrial subfraction (by 30% versus diluent-treated group; n=3/group; P=0.026; Figure 1D ), with increased colocalization of endogenous TRAF2 and mitochondrial proteins in punctate GFP-LC3-labeled autophagosomes ( Figure  1E ; Figure IIA to IIC in the Data Supplement). TRAF2 also colocalizes with ubiquitin ( Figure 1F ; Figure IID in the Data Supplement) and mitophagy adaptor protein, p62 ( Figure 1G ; Figure IIE in the Data Supplement), 11 in GFP-LC3-labeled autophagosomes in unstimulated NRCMs; and this colocalization was further stimulated by TNF treatment, suggesting that TRAF2 may participate in ubiquitination of mitochondrial proteins and autophagic sequestration of damaged mitochondria in both resting and TNF-treated cells.
In parallel studies, we also found that TRAF2 cosegregates with COX IV in mitochondria-enriched subfraction from wildtype mouse hearts ( Figure 1H ); and its abundance is increased in the cardiac mitochondrial fraction of transgenic mice with cardiac restricted overexpression of TNF (fold change in TRAF2/COX IV compared with control: 3.2±0.4-fold in MHCsTNF mice versus 1.0±0.1 in littermates; P=0.005; n=3/ group; Figure 1H ). Indeed, similar to the observations with TNF treatment of NRCMs, total TRAF2 abundance is transcriptionally induced in MHCsTNF transgenic hearts ( Figure 1I and 1J; Figure IIIA in the Data Supplement), along with increased autophagosome-bound LC3-II ( Figure 1I ; Figure IIIB in the Data Supplement). Interestingly, the increase in total LC3 and p62 protein abundance ( Figure 1I ; Figure Figure IVC in the Data Supplement) in the MHCsTNF myocardium as compared with littermate controls, indicating reduced mitochondrial mass, likely as a result of upregulated mitochondrial autophagy. Taken together, these data confirm that TNF induces TRAF2 expression with evidence of autophagic sequestration of mitochondria, which raises the interesting possibility that TNF and TRAF2-induced mitophagy may contribute to the reduced mitochondrial mass observed in MHCsTNF mouse hearts.
Exogenous TRAF2 Is Sufficient to Induce Mitochondrial Autophagy
To determine whether TRAF2 is sufficient to stimulate autophagy in cardiac myocytes, we adenovirally transduced NRCMs with TRAF2 and evaluated distribution of GFP-tagged LC3. As shown, exogenous TRAF2 expression induced autophagosome formation resulting in increased GFP-tagged LC3 puncta, as compared with control ( Figure 2A ). TRAF2 overexpression (≈10-fold compared with endogenous levels; Figure 2B ) induced a decline in endogenous LC3-II levels ( Figure 2B and 2C), with a decline in total LC3 abundance (fold change in total LC3/GAPDH compared with control: 0.51±0.09 in Ad-TRAF2 versus 1.0±0.03 in Ad-LacZ-treated controls; P<0.001; N=7/ group; Figure 2B ). Taken together with the accumulation of LC3-II and p62 ( Figure 2B to 2D) in the presence of Bafilomycin A1 (to inhibit lysosomal acidification), these data indicate that TRAF2 stimulates autophagy with intact flux. Exogenous TRAF2 colocalized with GFP-tagged punctate LC3 ( Figure  2E to 2G; Figure IIF in the Data Supplement), p62 ( Figure  2E ), and ubiquitin ( Figure 2F ) in ring-shaped structures, many Figure 2H ). We also observed occasional amorphous dense deposits within TRAF2-transduced cardiac myocytes by electron microscopic analysis. Such deposits are observed in mice with transgenic expression of high levels of TRAF2 in the mouse myocardium, 27 and may represent the aggregates of ubiquitinated cytoskeletal proteins observed in the MHCsTNF hearts. 28 Although this observation suggests a more generalized role for TRAF2 downstream of TNF signaling in protein ubiquitination, these data, taken together, indicate that TNF-induced upregulation of TRAF2 is also involved in ubiquitination of mitochondrial proteins targeted for autophagic sequestration.
Exogenous TRAF2 provoked a decline in mitochondrial mass assessed by cardiolipin content (with expression of nonylacridine orange, NAO; Figure 3A and 3B), mitochondrial protein abundance ( Figure 3C and 3D), and mitochondrial DNA content ( Figure 3E ); which was prevented by treatment with 3-methyl adenine (3MA, a PI3Kinase III inhibitor, 29 which inhibits autophagosome formation). Also, TRAF2 overexpression led to reduced citrate synthase activity (100.7±7.8 versus 147.8±4.1 nmol/mg per minute in LacZ-treated controls; P=0.006; n=3/group), indicating that exogenous TRAF2 is sufficient to provoke autophagic removal of mitochondria. . To examine the role of endogenous TRAF2 in TNF-induced mitophagy, we adenovirally transduced NRCMs with shRNA targeting rat TRAF2 (or LacZ as nontargeting control; Figure 4A ) and assessed total mitochondrial mass and relative content of depolarized mitochondria. Interestingly, knockdown of endogenous TRAF2 provoked a significant increase in NAO expression and mitochondrial DNA content not only in TNF-treated but also in diluent-treated NRCMs ( Figure 4B to 4D), with increased citrate synthase activity (310.6±20.1 with TRAF2shRNA versus 171.7±12.8 nmol/ mg per minute in LacZshRNA control; P=0.005; n=3/group) in diluent-treated NRCMs, indicating that TRAF2 knockdown results in increased mitochondrial mass. To assess whether increased mitochondrial biogenesis was contributing to the observed increase in mitochondrial mass, we examined the transcript levels for PGC1α and PGC1β, 2 transcriptional coactivators essential for mitochondrial biogenesis in cardiac myocytes. 30 TRAF2 knockdown was associated with a significant decline in the expression of PGC1α and PGC1β ( Figure  VI in the Data Supplement) as compared with controls, suggesting suppression of the mitochondrial biogenesis program, likely in response to accumulation of damaged mitochondria with TRAF2 knockdown. Indeed, TRAF2 knockdown resulted in a relative increase in depolarized mitochondria in diluenttreated NRCMs, evidenced by a significant increase in expression of JC-1 monomers (fluoresce green, right lower quadrant in Figure 4E and 4F) with concomitant loss of JC-1 aggregates (cells that fluoresce both red and green, right upper quadrant), indicating loss of mitochondrial inner membrane potential. These observations with TRAF2 knockdown mirror the effect of 3MA treatment to inhibit basal autophagy in resting cells, which also results in accumulation of depolarized mitochondria ( Figure VII in the Data Supplement) and increased mitochondrial mass ( Figure VA to VC in the Data Supplement). 31 Importantly, the relative increase in NAO expression with TRAF2 knockdown (as compared with LacZshRNA-treated control) was significantly more in TNF-treated as compared with diluent-treated controls (3.4±0.4 versus 1.5±0.1-fold compared with respective LacZshRNA group; P<0.001; N=7/group; Figure 4B and 4C) with a trend toward increase in mitochondrial DNA content (2.7±0.2 versus 2.2±0.1-fold compared with respective LacZshRNA-treated group; P=0.07; N=6/group; Figure 4D ). Also, TRAF2 knockdown resulted in significantly increased content of depolarized mitochondria in TNF-treated as compared with diluent-treated NRCMs 
Endogenous TRAF2 Is Essential for Removal of Mitochondria With TNF Treatment
Endogenous TRAF2 Is Essential for Homeostatic Clearance of Depolarized Mitochondria
The observation that TRAF2 knockdown increases mitochondrial mass and depolarization without inducing the mitochondrial biogenic program in resting cells (vide supra) indicates accumulation of damaged mitochondria with TRAF2 deficiency. To confirm this finding, we examined the mitochondrial ultrastructure in NRCMs transduced with TRAF2shRNA, and found a striking accumulation of degenerating structures containing mitochondria-like crista within multiple membranes, often in an onion skin-like whorled appearance ( Figure 4G ). Conceivably, these structures represent damaged mitochondria in various stages of degeneration, when their well-orchestrated autophagic removal is prevented in the absence of TRAF2.
Previous studies have demonstrated a central role for PINK1 in sensing mitochondrial damage to facilitate recruitment of an E3 ubiquitin ligase, PARKIN, to ubiquitinate mitochondrial proteins and target damaged mitochondria for autophagic degradation. 15 However, the lack of alteration in cardiac structure and function with detection of normally functioning cardiomyocyte mitochondria in unstressed PARK2 null young adult mice (with loss of PARKIN) 17 suggests redundancy with other ubiquitin ligases in their role in homeostatic mitochondrial autophagy in cardiac myocytes. Given our observations with accumulation of depolarized mitochondria with TRAF2 knockdown (Figure 4) , we tested the hypothesis that TRAF2, which is also an E3 ubiquitin ligase, plays an important role in autophagic removal of depolarized mitochondria in cardiac myocytes. We treated NRCMs with carbonyl cyanide m-chlorophenyl hydrazone (CCCP), an ionophore, that provokes loss of mitochondrial membrane potential and targets mitochondria for autophagic degradation. 15 Treatment with CCCP provoked progressive mitochondrial fragmentation with loss of mitochondrial potential-dependent mitotracker staining (pink, Figure 5A ), as described previously, 14, 15 and increased colocalization of endogenous TRAF2 (red) with depolarized mitochondria (identified by COX IV, green; with colocalization in yellow, Figure 5A ). Also, CCCP treatment provoked an increase in TRAF2 abundance in the mitochondria-enriched subcellular fraction, paralleling a relative increase in mitochondrial PARKIN abundance ( Figure 5B ). CCCP treatment provoked mitochondrial depolarization ( Figure 6A and 6B) and a decline in mitochondrial mass, as evidenced by a reduction in NAO fluorescence ( Figure 6C and 6D) with a trend toward reduced mitochondrial DNA content ( Figure 6E ). Notably, all parameters were markedly increased with concomitant 3MA treatment, indicating accumulation of CCCP-damaged mitochondria, when their autophagic removal is impaired. Importantly, TRAF2 knockdown also provoked an increase in depolarized mitochondria ( Figure 6A and 6B) with increased mitochondrial mass (assessed by NAO and mitochondrial DNA content; Figure 6D and 6E) in CCCP-treated NRCMs, mimicking the effects of 3MA treatment. Taken together, these data indicate that TRAF2 plays an essential role in homeostatic removal of depolarized mitochondria in cardiomyocytes.
TRAF2 Functions in Concert With PARKIN to Remove Damaged Mitochondria
Analogous to the observation that TRAF2 abundance is increased in the mitochondrial compartment with TNF stimulation ( Figure 1D Figure 5B) , these data indicate that as observed with PARKIN, 14 TRAF2 is also recruited to damaged mitochondria. Indeed, TRAF2 colocalizes with PARKIN on mitochondria in resting cardiomyocytes, presumably on damaged mitochondria ( Figure 7A , arrows; Figure IXA in the Data Supplement); and this colocalization is markedly enhanced with CCCP treatment, suggesting that TRAF2 and PARKIN are recruited together to depolarized mitochondria ( Figure 7A ; Figure IXA in the Data Supplement). Interestingly, previous studies suggest that PAR-KIN physically interacts with TRAF2 and ubiquitinates with it, independent of TRAF2's endogenous E3 ubiquitin ligase activity, to activate TRAF2-mediated signaling. 34 We have confirmed this physical interaction with a FRET (Forster resonance energy transfer) assay using a DsRed and AcGFP FRET pair-tagged TRAF2 and PARKIN, respectively (with controls in Figure IXB in the Data Supplement). The interaction between TRAF and PARKIN is minimal in the resting state (arrows, Figure 7B ) and is markedly enhanced in presence of CCCP-induced mitochondrial depolarization (arrows, Figure 7B ), suggesting increased interaction between these proteins on mitochondrial damage, which was confirmed via coimmunoprecipitation studies in the mitochondrial subfraction of CCCP-treated cells ( Figure IXC and IXD in the Data Supplement).
To examine the role of TRAF2 vis-à-vis PARKIN in mitochondrial autophagy, we transduced NRCMs with adenoviruses coding for shRNA targeting PARKIN ( Figure XA in the Data Supplement) in concert with exogenous TRAF2, and examined mitochondrial mass (by NAO expression) and prevalence of depolarized mitochondria (by JC-1). PARKIN knockdown provoked accumulation of depolarized mitochondria with increased NAO expression ( Figure 7C and 7D) and of JC-1 monomers ( Figure 7E ) in the resting state, with further increase observed with CCCP-induced depolarization. Exogenous expression of full length TRAF2, but not TRAF2 mutants deficient in E3 ubiquitin ligase activity (TRAF2-Rm and ΔN-TRAF2; Figure XI in the Data Supplement), 7, 35, 36 partially attenuated the increase in NAO expression ( Figure  7C and 7D) and abundance of depolarized mitochondria ( Figure 7E ) in CCCP-treated NRCMs transduced with PARKINshRNA (by ≈44% and 22%, respectively). Similarly, expression of exogenous TRAF2, but not the E3 ubiquitin ligase-deficient mutants, was sufficient to partially attenuate the accumulation of mitochondria in TNF-treated NRCMs transduced with PARKINshRNA ( Figure XIIA and XIIB in the Data Supplement). Therefore, TRAF2 can partially complement PARKIN deficiency as an E3 ubiquitin ligase to promote mitochondrial autophagy.
We next evaluated whether PARKIN can substitute for TRAF2 in promoting mitochondrial autophagy. Exogenous PARKIN ( Figure XB in the Data Supplement) is sufficient to provoke a decline in NAO expression ( Figure 7F and 7G) with a reduction in depolarized mitochondria in resting NRCMs (Figure 7H ), indicating that PARKIN overexpression is sufficient to facilitate autophagic removal of damaged mitochondria. Interestingly, exogenous PARKIN is also sufficient to partially restore mitochondrial autophagy in the setting of TRAF2 knockdown, as evidenced by a reduction in NAO expression (by ≈29%; Figure 7F and 7G) and depolarized mitochondria (by ≈40%; Figure 7H ), when compared with TRAF2-deficient cells treated with Ad-LacZ as control. Notably, endogenous levels of TRAF2 are only modestly increased in the setting of PARKIN knockdown, whereas PARKIN levels are not significantly altered when TRAF2 is knocked down, in vitro in NRCMs ( Figure XIIIA and  XIIIC) . This observation suggests that at least in vitro regulation of endogenous TRAF2 and PARKIN may be unable to compensate for each other deficiency, resulting in a defect in mitophagy when either is knocked down. Interestingly, mitochondrial proteins accumulate differentially with deficiency of TRAF2 or PARKIN, suggesting independent roles in ubiquitination and degradation of specific mitochondrial proteins for these E3 ubiquitin ligases ( Figure XIIIA and XIIID to XIIIF). Taken together, these findings suggest that TRAF2 functions as an E3 ubiquitin ligase in concert with PARKIN to facilitate ubiquitination of proteins on damaged mitochondria and assist in their removal through the process of autophagy ( Figure 7I ).
TRAF2 Facilitates Mitophagy to Confer Cytoprotection in Hypoxia/Reoxygenation Injury
ROS-induced mitochondrial permeabilization is implicated in provoking cardiomyocyte death in I/R injury. 8 To examine whether TRAF2 is recruited to the mitochondria with I/R-induced mitochondrial damage, we subjected mice to in vivo I/R modeling and performed subcellular fractionation on injured myocardial tissue. Interestingly, we observed a relative increase in TRAF2 abundance in the mitochondrial subfraction from the injured myocardium, early after I/R injury, paralleling that of PARKIN ( Figure 8A and 8B) . To determine the role of TRAF2 in mitochondrial autophagy in this setting, we examined subcellular location of TRAF2 and performed loss-of-function and gain-of-function modeling for TRAF2 in NRCMs subjected to hypoxia/reoxygenation injury, in vitro. Endogenous TRAF2 increasingly colocalized with depolarized mitochondria (with loss of mitotracker signal) in hypoxia/reoxygenation-injured NRCMs ( Figure 8C ). Knockdown of endogenous TRAF2 resulted in accumulation of depolarized mitochondria ( Figure 8D ) and increased cell death ( Figure 8F ) under normoxic conditions, which was markedly exacerbated with hypoxia/reoxygenation injury ( Figure 8D and 8F) . Conversely, exogenous TRAF2, but not its E3 ligase-deficient mutants (which are also mitophagy-deficient, vide supra), was sufficient to attenuate hypoxia/reoxygenation-induced cell death ( Figure  8G ) with a significant reduction in relative content of depolarized mitochondria ( Figure 8E ). Interestingly, exogenous expression of the E3 ligase-deficient mutants enhanced hypoxia/reoxygenation-induced cell death with increased content of depolarized mitochondria, paralleling our recent observations in ex vivo I/R injury, 37 indicating a dominant negative effect. Taken together, these data suggest a central role for TRAF2 as an E3 ubiquitin ligase in facilitating mitophagy as a mechanism for its observed cytoprotection with I/R injury.
Discussion
The results of the present study suggest that TRAF2 mediates mitochondrial autophagy through an E3 ligasedependent mechanism in both unstressed and stressed mammalian cardiomyocytes. The following lines of evidence support this conclusion. First, TRAF2 localizes to the mitochondria in quiescent cardiac myocytes and in native wild-type hearts. In the setting of TNF-induced mitochondrial damage, TRAF2 expression is transcriptionally upregulated with increased mitochondrial localization, both in vitro and in vivo ( Figure 1 ). Second, knockdown of endogenous TRAF2 results in the accumulation of depolarized mitochondria in resting cells, as well as in cells treated with TNF (Figure 4 ), the uncoupling agent CCCP ( Figure  6 ), and in cells subjected to hypoxia/reoxygenation injury (Figure 8 ), whereas exogenous TRAF2 is sufficient to facilitate autophagic removal of mitochondria in these settings (Figures 3, 4, and 8 ). Third, TRAF2 localizes to CCCPdepolarized mitochondria, where it interacts with PAR-KIN, a previously described mitophagy effector ( Figures  5 and 7) . Fourth, exogenous TRAF2 can partially restore mitophagy in the setting of PARKIN deficiency (Figure 7) , whereas overexpression of PARKIN can partially overcome the effects of TRAF2 deficiency with respect to mitophagy, suggesting a partial redundancy in the E3 ligase activity of TRAF2 and PARKIN to facilitate ubiquitination and degradation of mitochondrial proteins. Fifth, endogenous TRAF2 increasingly localizes to the mitochondria in hearts subjected to in vivo cardiac I/R injury and in cardiac myocytes subjected to hypoxia/reoxygenation, in vitro ( Figure  8 ). Finally, endogenous TRAF2 signaling is essential to prevent cardiomyocyte death with hypoxia/reoxygenation injury; and expression of exogenous TRAF2, but not its E3 ligase mutants, results in decreased abundance of depolarized mitochondria and enhanced cytoprotection with hypoxia/reoxygenation injury (Figure 8 ).
Mitophagy removes damaged mitochondria to protect against cell death in myocardial infarction 10 and neurodegeneration, 38 and is required for ischemic preconditioning in the myocardium. 11 Our findings indicate that TRAF2-mediated mitophagy may be a mechanism whereby endogenous TRAF2 signals downstream of either TNF receptor activation 7 to prevent cardiomyocyte death with hypoxia/reoxygenation injury, in vitro, 3 and with myocardial infarction, in vivo. 6 Also, TRAF2-mediated upregulation of mitophagy may further attenuate I/R-induced cardiomyocyte death, as observed in transgenic mouse hearts with cardiomyocytespecific expression of TRAF2 and TNF (at low levels) subjected to ex vivo I/R injury, 4 and facilitate the preconditioning effects of TNF administration on the myocardium, in vivo. 5 Conversely, the observed critical role for TRAF2 in mediating homeostatic mitophagy may explain the early lethality in TRAF2 null mice in the neonatal period, which is preceded by marked runting and elevated circulating TNF levels, with markedly increased cell death in various cell types. 39, 40 Our data point to an essential role for TRAF2 in parallel with PARKIN in facilitating mitophagy in cardiac myocytes. Activation of PARKIN, an E3 ubiquitin ligase, by PINK1 (a serine-threoine kinase) on damaged mitochondria has been ascribed an essential role in orchestrating their autophagic removal, and impaired homeostatic mitophagy has been implicated as the underlying mechanism for development of Parkinson disease in individuals harboring mutations in their respective genes. [13] [14] [15] However, studies in the heart reveal that although mice with cardiomyocyte-specific ablation of PINK1 demonstrate cardiomyopathy with markedly abnormal mitochondria, 16 loss of PARKIN (with PARK2 ablation) does not alter cardiac structure or function in young adult mice, 10 or increase susceptibility to in vivo I/R injury. 11 These observations suggest that PARKIN deficiency may be complemented by other proteins in the heart, and its deficiency becomes apparent only with a surge in mitochondrial damage as occurs with prolonged ischemia, 10 or cumulatively with aging. 17 Our data demonstrate that TRAF2 is present on the mitochondria in resting cardiomyocytes. In addition, TRAF2 has also been demonstrated to localize to the mitochondria on TNF receptor signaling associated with other proteins, namely TRADD, FADD, RIP1, and procaspase-8, in the death-inducing signaling complex 26 or complex II 41 ; and recent studies indicate that TRAF2 interacts with mitochondrial scaffolding proteins, such as mitochondrial antiviral signalosome, [19] [20] [21] whereby it would be positioned to participate in mitochondrial autophagy. Also, PARKIN interacts with TRAF2 ( Figure 7B) , and PARKIN-mediated ubiquitination has been demonstrated to activate TRAF2 in fibroblasts. 34 Given our observation that damaged mitochondria accumulate with TRAF2 deficiency, mimicking the effects of PARKIN knockdown, we posit that TRAF2 functions in concert with PARKIN in ubiquitinating mitochondrial proteins on mitochondrial damage (as proposed in Figure 7I ). Notably, although both exogenous PARKIN and TRAF2 are sufficient to partially restore mitophagy with each other deficiency, in vitro ( Figure 7C to 7H), mitochondrial proteins accumulate differentially with individual deficiencies of TRAF2 and PARKIN ( Figure XIII in the Data Supplement), suggesting both unique and redundant roles for TRAF2 vis-a-vis PARKIN. Further studies are required to clarify the molecular mechanism for recruitment of TRAF2 to damaged mitochondria, and determine whether PARKIN-mediated ubiquitination of TRAF2 is necessary to activate TRAF2 signaling; or TRAF2 functions independently of and in parallel to PARKIN in cardiomyocyte mitophagy. In addition, whether TRAF2-mediated ubiquitination is also required for removal of nonmitochondrial proteins via autophagy or ubiquitin-proteasome pathway needs to be explored.
Recent studies indicate that preventing removal of damaged mitochondria and mitochondrial DNA induces proinflammatory signaling. 42, 43 In this context, it is notable that TRAF2 null mice die of colitis with widespread bowel wall inflammation within the first 3 weeks of life, 39 and treatment with antibiotics or concomitant TNF receptor 1 ablation only partially rescues the inflammatory colitis 39 with a modest prolongation of lifespan. 44 In addition, concomitant ablation of TNF does not attenuate the chronic inflammatory state observed in various organ systems of the TRAF2 null mice, 45 indicating that the primary driver of the pathogenesis is downstream of the inflammatory mediators activated with loss of TRAF2. Intriguingly, mutations in genes that play critical roles in autophagic signaling have been implicated in loss of autophagy in enterocytes, leading to development of colitis and Crohn disease. [46] [47] [48] Therefore, impairment in homeostatic removal of damaged mitochondria may be the underlying mechanism for development of colitis and multiorgan inflammation in TRAF2-deficient mice, a premise which requires further experimental validation.
TRAF2 plays a prosurvival key role as an adaptor protein to transduce activation of kinases and transcription factors downstream of multiple innate immunity receptors. 1, 7, 41 The results of the present study extend these prior observations 4 and suggest a novel cytoprotective role for TRAF2 in mediating mitochondrial autophagy through an E3 ligase-dependent mechanism. Unraveling the role for innate immunity pathways with respect to regulation of mitochondrial mass and mitochondrial quality control may provide important insights in understanding the molecular mechanisms of human disease, as well as developing targeted therapies to counteract untoward effects of sustained inflammatory signaling.
